Forest Submits Memantine NDA; 3 Studies With Cognitive Endpoint Underway
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest has three backup memantine studies underway should FDA require data beyond the two trials in the NDA for moderate to severe Alzheimer’s disease, Forest VP-Investor Relations Charles Triano said during a July 17 earnings call.